Our Impact.Lung cancer is the leading cause of cancer related death worldwide. Through improving lung biopsies, we help decrease the number of procedure-related complications while also facilitating the emerging field of personalized treatment for lung cancer patients.
|
The Problem.
Over 150,000 percutaneous lung biopsy procedures are performed every year in the US.
1 in 5 patients have their lung collapse, and 1 in 8 patients require a second biopsy procedure.
1 in 5 patients have their lung collapse, and 1 in 8 patients require a second biopsy procedure.
|
A critical procedure
Percutaneous lung biopsies are a critical procedure for tumor diagnosis and personalized medicine research. |
With universal challenges
The standard procedure uses a straight biopsy needle and system, resulting in the ability to only achieve straight paths. This makes it challenging to collect adequate tissue in regions that are obstructed by ribs or blood vessels. |
Resulting in significant consequences
Multiple punctures, suboptimal angle of entry, increased procedure time, among other factors, increase the risk of pneumothorax, a collapsed lung, occurring in over 20% of all patients. |
Our Solution. |
|
|
The first biopsy needle device
to enable an angled or straight path to access any site in only one pass |
TroCap Features.
01 Mechanically-controlled |
02 CT & Ultrasound compatible |
03 Straight & curved paths |
04 Universal workflow integration |
05 Airtight properties |
Revolutionizing biopsies.
By enabling safer, high-yield lung biopsy procedures, our device has the potential
to revolutionize the lung biopsy space.
to revolutionize the lung biopsy space.